Course Faculty, IAS–USA Staff, Scientific Leadership Board, and Governance Board

Financial Relationships With Ineligible Companies

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as "commercial interests") within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as "those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients." Below are the financial interests that faculty members of this course have had within the past 24 months. View the Faculty Financial Disclosure Policy.

Keeping Up With the Guidelines: Recommendations and Controversies in Sexually Transmitted Infection Management

May 20, 2025

Course Presenters and Panelists	
Paul C. Adamson, MD, MPH Professor of Medicine University of California Los Angeles Los Angeles, CA	Dr Adamson reported no relevant financial relationships with ineligible companies. (Updated April 30, 2025)
Jodie A. Dionne, MD, MSPH Associate Professor of Infectious Diseases University of Alabama at Birmingham Birmingham, AL	Dr Dionne reported no relevant financial relationships with ineligible companies. (Updated May 1, 2025)
Khalil G. Ghanem, MD, PhD Professor of Medicine The Johns Hopkins University Baltimore, MD	Dr Ghanem reported no relevant financial relationships with ineligible companies. (Updated April 17, 2025)
Timothy J. Wilkin, MD, MPH Professor of Medicine University of California San Diego La Jolla, CA	Dr Wilkin reported receiving research grants from Merck & Co, Inc, and serving as a consultant for ViiV Healthcare and Merck & Co, Inc. (Updated November 9, 2024)

IAS–USA CME Planners and Reviewers	
Raphael J. Landovitz, MD, MSc Professor of Medicine David Geffen School of Medicine at UCLA Director, UCLA Center for Clinical AIDS Research & Education University of California Los Angeles	Dr Landovitz reported serving as a consultant for Gilead Sciences, Inc, Merck & Co, Inc, RedQueen Therapeutics, and ViiV Healthcare. (Updated May 5, 2025)
Susanna Naggie, MD, MHS Professor of Medicine Vice Dean for Clinical Research Duke University School of Medicine Durham, NC	Dr Naggie reported serving as a consultant for Vir Biotechnology and receiving fees from Bristol-Myers Squibb. She has stock options of Vir Biotechnology. (Updated May 9, 2024)
Donna M. Jacobsen Executive Director/President IAS–USA San Francisco, CA	Ms Jacobsen reported no relevant financial affiliations with ineligible companies to disclose. (Updated May 5, 2025)

IAS–USA Boards
The nonstaff members of the IAS–USA Scientific Advisory Board and Governance Board are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.